rs12095080 — DIO1 DIO1 cardiac mortality variant

DIO1 and the Cardiac Thyroid Axis — When Local T3 Drops After a Heart Attack

The heart is among the most metabolically active organs in the body, and triiodothyronine (T3)¹¹ triiodothyronine (T3)
the active form of thyroid hormone that directly enters cardiomyocyte nuclei and regulates gene transcription is one of its principal regulators. T3 governs cardiac contractility, heart rate, coronary vasodilation, and — critically — the regenerative response to ischemic injury. The DIO1 gene encodes type 1 iodothyronine deiodinase²² type 1 iodothyronine deiodinase
a selenoprotein enzyme expressed in liver, kidney, thyroid, and to a lesser extent cardiac tissue, one of three deiodinase enzymes responsible for converting the inactive prohormone T4 into active T3 in peripheral tissues.

The rs12095080 variant sits in the 3' untranslated region of DIO1, a regulatory segment that influences how efficiently the mRNA is translated into functional enzyme. Carriers of the G allele appear to have altered DIO1 activity that reduces T4→T3 conversion, creating a tissue-level hypothyroid state³³ tissue-level hypothyroid state
where serum TSH can be normal while cardiomyocytes receive less T3 than required for optimal function. This genetic predisposition becomes acutely dangerous in the context of myocardial infarction, when the cardiac thyroid axis is already under physiological stress.

The Mechanism

DIO1 is a selenocysteine-containing enzyme⁴⁴ selenocysteine-containing enzyme
requiring dietary selenium for its active site that catalyzes the outer-ring deiodination of T4 to T3. The rs12095080 G allele falls in the 3' UTR — a region that controls mRNA stability, translational efficiency, and microRNA binding. 3' UTR variants can reduce the half-life of messenger RNA or impair ribosomal loading⁵⁵ reduce the half-life of messenger RNA or impair ribosomal loading
resulting in lower steady-state protein levels without any change in the protein sequence. Lower DIO1 protein levels mean less T4→T3 conversion in the liver and periphery, reducing the systemic pool of active T3 available to the heart.

During and after acute myocardial infarction, non-thyroidal illness syndrome⁶⁶ non-thyroidal illness syndrome
also called low-T3 syndrome, a transient suppression of T4 deiodination driven by ischemic stress, inflammatory cytokines, and cortisol compounds this baseline genetic deficiency. Cardiomyocytes deprived of T3 show impaired sarco-endoplasmic reticulum calcium ATPase (SERCA2a)⁷⁷ sarco-endoplasmic reticulum calcium ATPase (SERCA2a)
the pump that cycles calcium between cytosol and SR to enable muscle relaxation expression, slower myosin heavy chain isoform switching toward the efficient β-MHC form, and reduced capacity for post-ischemic repair.

The Evidence

The primary evidence for rs12095080 comes from a 2020 longitudinal study by Kazukauskiene et al.⁸⁸ 2020 longitudinal study by Kazukauskiene et al.
published in Scientific Reports following 290 patients with acute myocardial infarction over a multi-year period. After controlling for NT-pro-BNP, ejection fraction, and other standard prognostic variables, the AG genotype at rs12095080 independently predicted cardiac-related mortality with an odds ratio of 3.97 (95% CI 1.45–10.89; p = 0.005)⁹⁹ odds ratio of 3.97 (95% CI 1.45–10.89; p = 0.005)
a nearly 4-fold increase in mortality risk. The overall variant (any G allele) carried a hazard ratio of 1.74 (95% CI 1.04–2.91; p = 0.034)¹⁰¹⁰ hazard ratio of 1.74 (95% CI 1.04–2.91; p = 0.034) as an independent predictor. The same group previously found rs12095080 associated with hypertension prevalence¹¹¹¹ rs12095080 associated with hypertension prevalence
in the same AMI cohort, suggesting broader cardiovascular vulnerability.

The genetic finding is reinforced by extensive evidence linking low T3 syndrome to cardiac outcomes independent of the variant. A 2017 meta-analysis of 41 studies by Wang et al.¹²¹² 2017 meta-analysis of 41 studies by Wang et al.
International Journal of Cardiology found that low-T3 syndrome in cardiovascular patients was associated with cardiac mortality HR 2.06 (95% CI 1.58–2.69)¹³¹³ cardiac mortality HR 2.06 (95% CI 1.58–2.69)
and all-cause mortality HR 2.52. In a large 2018 propensity-matched analysis of 2,459 AMI patients¹⁴¹⁴ 2018 propensity-matched analysis of 2,459 AMI patients
J Cardiol, low-T3 syndrome (prevalence 23.3%) was associated with in-hospital cardiovascular death rates of 4.7% vs. 1.7% in euthyroid controls, and adding the T3 status to the TIMI risk score meaningfully improved mortality prediction.

Important caveats: the rs12095080 cardiac mortality association comes from a single study with 290 patients from a Lithuanian AMI cohort. Replication in other populations and larger samples is needed before this variant reaches a higher evidence grade. The G allele is also notably rare in East Asian populations (essentially absent), so these findings may not generalize across all ancestries.

Practical Actions

If you carry the G allele, the central actionable priority is thyroid hormone monitoring — specifically free T3 (fT3), not just TSH and fT4. TSH is normal in low-T3 syndrome, making standard thyroid panels uninformative. Requesting an fT3 level as part of routine cardiovascular assessment establishes your baseline and provides meaningful prognostic context.

Selenium is the critical dietary cofactor for all three deiodinase enzymes. DIO1 is a selenoprotein — its catalytic activity depends on adequate selenium availability. Brazil nuts (one or two per day) provide the daily requirement¹⁵¹⁵ Brazil nuts (one or two per day) provide the daily requirement
each nut contains ~70–90 µg selenium; excess selenium is toxic, so do not exceed 400 µg/day. Selenium-containing foods and supplementation at 100–200 µg/day support baseline deiodinase capacity.

In any cardiac event or major illness, low-T3 syndrome develops rapidly and dramatically worsens outcomes. Ensuring your cardiologist is aware of this genetic finding before any planned cardiovascular procedures allows pre-emptive thyroid monitoring during hospitalization.

Interactions

DIO1 rs12095080 acts within the broader thyroid hormone metabolism pathway, which includes DIO2 (type 2 deiodinase¹⁶¹⁶ DIO2 (type 2 deiodinase
expressed in cardiac tissue and the brain, plays a complementary T4→T3 conversion role) and DIO3 (type 3 deiodinase¹⁷¹⁷ DIO3 (type 3 deiodinase
the inactivating enzyme that converts T3 to reverse T3). Variants in DIO2 (rs225014, rs2235544) and DIO3 (rs945006) may compound the effect of rs12095080 by further disrupting T3 availability. Additionally, SLCO1C1/OATP1C1 variants¹⁸¹⁸ SLCO1C1/OATP1C1 variants
controlling thyroid hormone transport into cells interact with deiodinase activity to determine net intracellular T3 levels. Individuals with variants in multiple thyroid hormone metabolism genes face the greatest aggregate risk of tissue-level hypothyroidism under cardiac stress.